Myriad Genetics, Inc. (MYGN)
US — Healthcare Sector
Automate Your Wheel Strategy on MYGN
With Tiblio's Option Bot, you can configure your own wheel strategy including MYGN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MYGN
- Rev/Share 9.0605
- Book/Share 8.0495
- PB 0.5168
- Debt/Equity 0.1956
- CurrentRatio 1.9002
- ROIC -0.1225
- MktCap 383457984.0
- FreeCF/Share -1.1804
- PFCF -3.5737
- PE -3.2599
- Debt/Assets 0.1323
- DivYield 0
- ROE -0.1539
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 2
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | MYGN | Scotiabank | Sector Outperform | Sector Perform | -- | $6 | May 21, 2025 |
| Downgrade | MYGN | Wolfe Research | Outperform | Peer Perform | -- | -- | May 8, 2025 |
| Downgrade | MYGN | Wells Fargo | Overweight | Equal Weight | -- | $6 | May 7, 2025 |
| Downgrade | MYGN | Guggenheim | Buy | Neutral | -- | -- | April 9, 2025 |
| Upgrade | MYGN | Piper Sandler | Neutral | Overweight | $11.5 | $12.5 | March 12, 2025 |
| Initiation | MYGN | Craig Hallum | -- | Buy | -- | $29 | Feb. 12, 2025 |
| Initiation | MYGN | UBS | -- | Neutral | -- | $18 | Dec. 10, 2024 |
| Downgrade | MYGN | Leerink Partners | Outperform | Market Perform | $30 | $21 | Dec. 9, 2024 |
| Initiation | MYGN | Morgan Stanley | -- | Equal Weight | -- | $32 | Sept. 19, 2024 |
| Initiation | MYGN | Wells Fargo | -- | Overweight | -- | $35 | Aug. 28, 2024 |
News
Myriad Genetics (MYGN) Meets Q4 Earnings Estimates
MYGN
Published: February 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Published: February 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Myriad Genetics (MYGN) came out with quarterly earnings of $0.03 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.04 per share a year ago.
Read More
About Myriad Genetics, Inc. (MYGN)
- IPO Date 1995-10-06
- Website https://myriad.com
- Industry Medical - Diagnostics & Research
- CEO Mr. Samraat S. Raha
- Employees 2700
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.